Merz to present solid Xeomin data in movement disorders
Germany's Merz Pharmaceuticals will present statistically-significant results from two studies of its movement-disorder treatment Xeomin (NT-201) at the American Academy of Neurology's annual meeting in Seattle, Washington.
The prospective, double-blind placebo controlled multi-center studies include patients with cervical dystonia and blepharospasm, as well as pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity.
NT-201 is a botulinum neurotoxin type A free from complexing proteins approved for marketing in Europe since 2007 to treat various movement disorders, and recently cleared in Canada for the indications of symptomatic management of blepharospasm, cervical dystonia and post-stroke spasticity of the upper limb. Merz plans to file a Biologic License Application for the drug in the USA in the near future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze